Friday, June 28, 2019
Terns Pharmaceuticals, Inc. today is dedicated to discovering and developing innovative therapeutic / diagnostic solutions for metabolic and liver related diseases Announced exclusive license and collaboration agreement with biopharmaceutical company Genfy (GNFT) in late stage. Under the terms of the agreement, Terns develops and registers Elafibanol as a treatment for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) in Greater China (Mainland China, Hong Kong, Macao, Taiwan) -Acquire exclusive rights to sell. Jenphy receives $ 35 million in prepayments and then is entitled to up to $ 193 million in payments based on clinical, regulatory and commercial milestones. The two companies will also work together to advance NASH and PBC research and development. The targets of these research and development include the possibility of combining the dual agonist Elafibranol for peroxisome proliferator activated receptor alpha / delta (PPAR α / δ) with the candidate for development of Terns. These development candidates include TERN-101, a farnesoid X receptor (FXR) agonist, TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, and our thyroid hormone receptor (THR) beta-selective agonist and It includes programs for apoptosis signal-regulated kinase 1 (ASK1) inhibitors.
As Dr. Weidong Zhong, the CEO of Terns, says: "Terns is committed to bringing China and the rest of the world market new and innovative treatments for liver disease. The partnership with Jiffy is the next step we should take as a company We believe that combination therapy will soon become the standard of care for NASH, and our strategy is based on this conviction: Elafibranol is a compound that is in the late stages of development and its mechanism of action is owned by our company And is well-suited to our strategy to advance combination therapies for chronic liver disease by adding Elafibranol to our pipeline and expanding the focus areas of liver disease to include PBC. , A company that shares our goal of developing innovative therapeutics for liver disease, it will be possible to gain a strong partner named Genfy. It is a joy. "
"We are delighted to see you there," said Pascal Prigent, executive vice president of marketing and commercial development at Jenphy. "The Terns team combines a wealth of experience in drug development with an infrastructure for the successful development, registration and commercialization of new therapeutics in Asia. We have Elafibranol in Greater China We are highly trusted by Terns in acting to deliver to patients and collaborating on future research and development activities and strategies for combination therapy. "
The licensing and collaboration agreement with Jenphy follows the 2018 announcement that Terns has acquired a worldwide exclusive right to develop and commercialize three NASH assets from Eli Lilly and Company . Together, these contracts strengthen the pipeline through partnerships with local and global companies, as well as in-house drug discovery activities to realize and disseminate effective combination therapies for patients with chronic liver disease. It proves that the Terns are inclined.
